William Blair Has Positive Estimate for Amgen Q1 Earnings

Amgen Inc. (NASDAQ:AMGN) – Research analysts at William Blair raised their Q1 2025 earnings per share (EPS) estimates for shares of Amgen in a report released on Monday, April 14th. William Blair analyst M. Phipps now forecasts that the medical research company will post earnings per share of $3.95 for the quarter, up from their prior estimate of $3.89. The consensus estimate for Amgen’s current full-year earnings is $20.62 per share. William Blair also issued estimates for Amgen’s FY2026 earnings at $19.47 EPS.

A number of other analysts have also recently weighed in on AMGN. Citigroup reissued a “neutral” rating on shares of Amgen in a research report on Wednesday, February 5th. Morgan Stanley boosted their price target on Amgen from $328.00 to $330.00 and gave the stock an “equal weight” rating in a research note on Wednesday, April 9th. Piper Sandler increased their price objective on shares of Amgen from $310.00 to $329.00 and gave the company an “overweight” rating in a research report on Monday, February 10th. UBS Group boosted their target price on shares of Amgen from $315.00 to $319.00 and gave the stock a “neutral” rating in a research report on Monday, April 14th. Finally, Truist Financial decreased their price target on shares of Amgen from $333.00 to $298.00 and set a “hold” rating for the company in a report on Wednesday, January 8th. Two research analysts have rated the stock with a sell rating, nine have issued a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $314.91.

Amgen Trading Down 1.9 %

NASDAQ:AMGN opened at $277.29 on Thursday. The firm has a 50 day moving average of $303.04 and a 200 day moving average of $294.22. The company has a quick ratio of 0.95, a current ratio of 1.26 and a debt-to-equity ratio of 9.62. Amgen has a 52 week low of $253.30 and a 52 week high of $346.85. The stock has a market capitalization of $149.09 billion, a price-to-earnings ratio of 36.73, a PEG ratio of 2.63 and a beta of 0.59.

Amgen (NASDAQ:AMGN) last announced its earnings results on Tuesday, February 4th. The medical research company reported $5.31 EPS for the quarter, topping analysts’ consensus estimates of $5.04 by $0.27. Amgen had a net margin of 12.24% and a return on equity of 176.32%.

Institutional Investors Weigh In On Amgen

Large investors have recently made changes to their positions in the stock. Wells Trecaso Financial Group LLC lifted its position in Amgen by 4.9% during the first quarter. Wells Trecaso Financial Group LLC now owns 2,257 shares of the medical research company’s stock worth $703,000 after buying an additional 106 shares in the last quarter. Clarius Group LLC raised its holdings in shares of Amgen by 23.7% during the 1st quarter. Clarius Group LLC now owns 10,277 shares of the medical research company’s stock worth $3,202,000 after acquiring an additional 1,970 shares during the period. Planning Center Inc. acquired a new position in shares of Amgen during the 1st quarter valued at about $215,000. Birch Hill Investment Advisors LLC grew its holdings in shares of Amgen by 5.6% in the first quarter. Birch Hill Investment Advisors LLC now owns 2,160 shares of the medical research company’s stock valued at $673,000 after purchasing an additional 115 shares during the period. Finally, Bell Bank raised its stake in Amgen by 2.4% during the first quarter. Bell Bank now owns 31,470 shares of the medical research company’s stock worth $9,804,000 after purchasing an additional 737 shares during the period. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, EVP David M. Reese sold 25,225 shares of the stock in a transaction on Friday, February 21st. The stock was sold at an average price of $304.44, for a total value of $7,679,499.00. Following the completion of the transaction, the executive vice president now directly owns 36,922 shares of the company’s stock, valued at approximately $11,240,533.68. This represents a 40.59 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Jonathan P. Graham sold 25,045 shares of Amgen stock in a transaction on Friday, February 7th. The stock was sold at an average price of $293.12, for a total transaction of $7,341,190.40. Following the sale, the executive vice president now directly owns 28,987 shares in the company, valued at approximately $8,496,669.44. This trade represents a 46.35 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 69,341 shares of company stock worth $20,644,335. Corporate insiders own 0.69% of the company’s stock.

Amgen Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Friday, May 16th will be issued a $2.38 dividend. This represents a $9.52 annualized dividend and a yield of 3.43%. The ex-dividend date of this dividend is Friday, May 16th. Amgen’s payout ratio is 126.09%.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.